• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cachexia - Pipeline Review, H2 2011 - Product Image

Cachexia - Pipeline Review, H2 2011

  • Published: October 2011
  • 74 pages
  • Global Markets Direct

Cachexia - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Cachexia - Pipeline Review, H2 2011', provides an overview of the Cachexia therapeutic pipeline. This report provides information on the therapeutic development for Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cachexia. 'Cachexia - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cachexia.
- A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cachexia Overview
Therapeutics Development
An Overview of Pipeline Products for Cachexia
Cachexia Therapeutics under Development by Companies
Cachexia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Cachexia Therapeutics - Products under Development by Companies
Cachexia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Cachexia Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Eli Lilly and Company
Inovio Biomedical Corporation
Daiichi Sankyo Company, Ltd
BioLineRx, Ltd.
AEterna Zentaris Inc.
Galapagos NV
Helsinn Healthcare S.A.
NovImmune SA
Vicus Therapeutics, LLC
OHR Pharmaceutical Inc.
Acacia Pharma Ltd.
Rhythm Pharmaceuticals
Cachexia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
SUN11031 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEZS-130 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RM-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-5040 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NI-1201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-945429 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VGX-3200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kanglaite - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Remicade - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLPG0492 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ghrelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enbrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anamorelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APD209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-6020 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Testosterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VT-122 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OHR/AVR118 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VT-122 + Nexavar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MT-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revlimid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY2495655 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Remicade + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cachexia Therapeutics – Drug Profile Updates
Cachexia Therapeutics - Discontinued Products
Cachexia - Featured News
Jul 20, 2011: Galapagos Initiates Proof-of-Mechanism Clinical Study Of Candidate Cachexia Drug GLPG0492
May 17, 2011: Ohr Pharmaceutical Receives Canadian Composition-of-Matter Patent For OHR/AVR118
Mar 17, 2011: PsiOxus Therapeutics Initiates Phase II Clinical Study Of Wasting Disease Therapeutic MT-102
Dec 27, 2010: Vicus Initiates Phase II Trial To Evaluate VT-122 In Patients With Liver Cancer Receiving Nexavar
Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics
Dec 14, 2010: Ohr Enrolls First Three Patients In Phase IIb Cachexia Trial
Dec 02, 2010: Galapagos Successfully Completes First-In-Human Trial Of GLPG0492 In Cachexia Patients
Nov 03, 2010: Ohr Pharmaceutical Inc. Announces $244,000 Grant Award
Aug 11, 2010: Centocor Ortho Biotech's Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE Demonstrate Marked Clinical Improvement
Jul 30, 2010: Formatech To Provide Services To Formulate And Fill Femta's FM101 Under Fillanthropy Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos